The two units reported unaudited revenues of €19.9 million for the year ended 31 December 2024, an increase from €18.6 million in 2023. hVIVO's full-year revenue guidance for 2025 is £73 ...

Hvivo anticipates that full-scale Hmpv human challenge trials (HCTs) could commence in the second half of 2025 ...

Listed clinical trials group Hvivo has been selected to carry out a human trial for a whooping cough vaccine in what is expected to be the largest such exercise it has ever conducted. The company ...

Research firm HVIVO has announced that it hopes to commence the final stage of its study on human metapneumovirus (HMPV) ...

hVIVO is a specialist contract research organization (CRO) and a world leader in human challenge models. A human challenge trial overcomes the complexities associated with conducting traditional ...

Nova Minerals identifies new high-grade zone with samples up to 52.3 g/t at Estelle Gold and Critical Minerals Project ...

The UK market has faced challenges recently, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. In such a climate ...

Clinical trials company Hvivo has completed its first acquisition, buying two research units from German group CRS for €10 million. Hvivo, which specialises in early-stage drug development ...

Pharmaceutical services firm hVivo, formerly Open Orphan, has acquired two clinical trial units in Germany from CRS Clinical Research Services Management GmbH for a cash consideration of €10m.